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Background: Long-term oral corticosteroid (OCS) therapy is associated with significant burden
on patients and healthcare resources; treatments that may help reduce their use are impor-
tant to improve asthma management.
Methods: French and German clinicians prescribing omalizumab for >16 weeks to patients
with severe persistent allergic asthma collected OCS use data. OCS use was recorded at base-
line and at a non-specific time point beyond 16 weeks from initiation of omalizumab. The
number of asthma exacerbations (FEV1 < 60% of personal best, requiring OCS burst and
unscheduled doctor/emergency visit or hospitalization) and asthma-related hospitalizations
during the 12-months prior to omalizumab treatment and during the observation period were
also recorded.
Results: Overall, 346 patients were treated with omalizumab for >16 weeks. Of these, 166
(48.0%) were receiving maintenance OCS (France, n Z 64; Germany, n Z 102). Following
omalizumab therapy, 84 (50.6%) patients on OCS at baseline reduced/stopped OCS dose at
the time of data collection; 34 (20.5%) stopped and 50 (30.1%) reduced OCS. In all patients
receiving maintenance OCS at baseline, mean reduction from baseline in daily OCS dose was
29.6% (7.1 mg prednisolone). In patients who reduced/stopped maintenance OCS, mean reduc-
tion from baseline in daily OCS dose was 74.3% (15.4 mg prednisolone). Reductions in) 5 57 5715 60; fax: þ33 (0) 5 57 57 46 71.
@pharmaco.u-bordeaux2.fr (M. Molimard).
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1382 M. Molimard et al.exacerbations and hospitalizations were observed from the 12-months prior to baseline in
patients at the time of data collection, irrespective of change in OCS dose.
Conclusion: European real-life experience demonstrates the OCS-sparing potential of
omalizumab in some patients with severe allergic (IgE-mediated) asthma.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Despite the use of high-dose inhaled corticosteroids (ICS)
and long-acting b2-agonists (LABA), patients with severe
allergic asthma can remain inadequately controlled.1,2
Maintenance oral corticosteroids (OCS) are frequently
administered to achieve control in these patients; however,
regular OCS use is associated with significant systemic side
effects including cataracts, high blood sugar among non-
diabetics, osteoporosis, acne, weight gain, sleep and mood
disturbances.3,4
Treatments that allow reductions in systemic steroid use
are important to the overall management of patients with
severe persistent asthma, as they can help reduce the
burden associated with long-term steroid therapy.3,4 The
addition of anti-leukotrienes to ICS can improve asthma
control, although the OCS-sparing effect is minimal.5 Also,
experimental drugs which may have an OCS-sparing effect,
including cyclosporin or methotrexate, have failed to
demonstrate an acceptable risk: benefit ratio.6,7
Omalizumab (XOLAIR, Novartis Pharma AG, Basel,
Switzerland) is a humanized anti-immunoglobulin E (IgE)
monoclonal antibody approved in the EU as add-on therapy
for the treatment of adults and adolescents with inade-
quately controlled severe allergic (IgE-mediated) asthma.8
In the EU, the indication has recently been extended
to include children (6e<12 years) with severe allergic
(IgE-mediated) asthma.8
Omalizumab has been shown to reduce asthma exacer-
bations, improve lung function and overall quality of life.1,2
By reducing exacerbations, often requiring treatment with
OCS, it may also reduce the need for rescue and mainte-
nance OCS.9
Datadescribing real-life experiencewithomalizumabhave
been reported from France,10 the UK,11 and Germany.12
This analysis explores the maintenance OCS-sparing
potential of omalizumab using a pooled analysis of findings
from real-life experiences of French and German clinicians.Methods
Patients
French data were obtained from patients who had received
omalizumab on compassionate grounds before its commer-
cialization in France, details have been published previ-
ously.10 German data were obtained from patients treated
with omalizumab during post-marketing surveillance,
details have been published previously.12 Omalizumab was
administered according to a dosing table nomogram incor-
porating the patients’ bodyweight and baseline IgE levels.
The previously reported UK real-life data11 were not of
sufficient detail to be included in this pooled analysis.Study assessments
Baseline (prior to commencing omalizumab therapy)
and final (non-specific time point beyond 16 weeks of
omalizumab therapy) OCS doses (prednisolone equivalents)
were collected in patients who continued omalizumab
therapy for more than 16 weeks.
The following data were also collected:
e baseline demographics and asthma medication
e prescribed omalizumab dose
e number of asthma exacerbations (as defined by decline
in FEV1 to <60% of personal best, requiring an OCS burst
and unscheduled doctor/emergency visit or hospitali-
zation) and asthma-related hospitalizations during the
12-months prior to omalizumab treatment and during
the observation period.
Statistical analyses
Summary statistics describing change from baseline in OCS
dose and annualized number of asthma exacerbations and
asthma-related hospitalizations were calculated for all
patients receiving maintenance OCS therapy at baseline
and for the subgroups of patients who had their OCS
dose reduced/stopped or maintained/increased during
omalizumab treatment.
Results
Patient disposition and baseline characteristics
A total of 346 patients received omalizumab therapy for
more than 16 weeks (France, nZ 108; Germany, nZ 238).
Of these, 166 (48.0%) were taking maintenance OCS at
baseline (France, n Z 64 [59.3%]; Germany, n Z 102
[42.9%]). Baseline demographics of those patients receiving
maintenance OCS at baseline were mostly similar for the
French and German patients (Table 1). No post-baseline
data were available for one patient from the German
group.
The majority of patients were receiving regular treat-
ment with ICS (97.6%) and LABA (95.8%) either as mono-
therapy or ICS/LABA combination therapy. On average
serum total IgE levels were higher in German patients who
therefore received a greater mean [SD] omalizumab dose
compared with French patients (736.6 [522.68] vs. 387.5
[189.61] mg/month). Mean [SD] duration of omalizumab
therapy was longer in French compared with German
patients (305.0 [170.69] vs. 213.0 [185.97] days). At
baseline, the mean prescribed daily dose of OCS was
higher in France (26.5 mg) compared with Germany
(14.3 mg).
Table 1 Baseline demographic and asthma medication (patients requiring maintenance OCS at baseline).
French (n Z 64) German (n Z 102) Combined (n Z 166)
Age, years Mean (SD) 47.5 (12.44) 45.1 (14.77) 46.1 (13.92)
Sex, n (%)
Female 37 (57.8) 54 (52.9) 91 (54.8)
Weight, kg
Mean (SD) 72.0 (13.91) 72.7 (18.44) 72.4 (16.77)
Serum total IgE, IU/mL
Mean (SD) 273.5 (234.65) 374.1 (396.80) 335.3 (346.14)
ICS use, n (%)a 63 (98.4) 99 (97.1) 162 (97.6)
LABA use, n (%)a 63 (98.4) 96 (94.1) 159 (95.8)
ICS, inhaled corticosteroids; LABA, long-acting b2-agonist; OCS, oral corticosteroids; SD, standard deviation.
a Monotherapy and/or ICS/LABA combination therapy.
Omalizumab reduces oral corticosteroid use 1383Effect of omalizumab on OCS use
Overall, 84 (50.6%) patients stopped or reduced their OCS
dose at the time of data collection; 34 (20.5%) stopped and
50 (30.1%) reduced OCS dose. OCS dose was maintained in
71 (42.8%) patients and increased in 10 (6.0%). The mean
reduction from baseline in OCS dose was 7.1 mg (29.6%)
(Table 2). The mean baseline and final doses (at time of
data collection) of OCS were 19.0 mg and 12.0 mg,
respectively. In patients who reduced or stopped OCS use,
the mean reduction from baseline in OCS dose was 15.4 mg
(74.3%) (Table 2); the mean baseline and final doses of OCS
were 22.8 mg and 7.5 mg, respectively. In the 50 patients
who reduced OCS use, the mean reduction from baseline in
OCS dose was 16.5 mg (56.9%); the mean baseline and finalTable 2 Change from baseline in OCS dose in patients receivin
Overall
population
France
Mean baseline dose, mg (SD) 26.5 (19.36)
Mean final dose, mg (SD) 17.8 (17.75)
Absolute change,b mg (SD) 8.7 (14.63)
Percentage change, % (SD) 30.3 (47.06)
[n Z 64]
Germanya
Mean baseline dose, mg (SD) 14.3 (11.86)
Mean final dose, mg (SD) 8.3 (9.92)
Absolute change,b mg (SD) 6.0 (10.41)
Percentage change, % (SD) 29.2 (83.35)
[n Z 102]
Combined
Mean baseline dose, mg (SD) 19.0 (16.27)
Mean final dose, mg (SD) 12.0 (14.23)
Absolute change,b mg (SD) 7.1 (12.25)
Percentage change, % (SD) 29.6 (71.32)
[n Z 166]
OCS, oral corticosteroids; SD, standard deviation.
a No post-baseline data were available for one patient.
b Prednisolone equivalents.doses of OCS were 29.0 mg and 12.5 mg, respectively. In
patients who maintained or increased OCS use, the mean
increase from baseline in OCS dose was 1.5 mg (16.7%).
Similar changes in OCS use were observed in patients,
whether from France or Germany (Table 2).
Effect of omalizumab on exacerbations and
hospitalizations
Reductions in exacerbations and hospitalizations were
observed from the 12-months prior to baseline in patients at
the time of data collection; irrespective of change in OCS
dose (Tables 3 and 4). Themean baseline and final number of
exacerbations/patient/year and hospitalizations/patient/
year were 5.7 and 1.9, and 1.0 and 0.5, respectively.g maintenance OCS at baseline.
Mean change in OCS dose
Patients who
reduced/stopped
OCS
Patients who
maintained/
increased OCS
29.5 (21.35) 23.1 (16.54)
11.3 (15.38) 25.1 (17.60)
18.2 (13.63) 2.0 (5.34)
65.9 (30.35) 10.1 (24.18)
[n Z 34] [n Z 30]
18.3 (13.12) 10.5 (9.15)
4.9 (7.81) 11.7 (10.67)
13.4 (8.39) 1.2 (6.27)
80.0 (23.06) 20.6 (90.90)
[n Z 50] [n Z 51]
22.8 (17.70) 15.1 (13.76)
7.5 (11.83) 16.7 (15.04)
15.4 (11.00) 1.5 (5.92)
74.3 (26.99) 16.7 (73.50)
[n Z 84] [n Z 81]
Table 3 Asthma exacerbationsa in patients receiving maintenance OCS at baseline.
Exacerbations/patient/year
Overall population Patients who
reduced/stopped
OCS
Patients who
maintained/
increased OCS
France
Pre-omalizumab,b mean (SD) 6.1 (7.27) [n Z 53] 5.1 (4.15) [n Z 30] 7.3 (9.98) [n Z 23]
Post-omalizumab,c mean (SD) 3.8 (5.50) [n Z 57] 3.3 (5.22) [n Z 32] 4.4 (5.88) [n Z 25]
Change, mean (SD) 2.0 (6.00) [n Z 50] 1.8 (6.80) [n Z 30] 2.2 (4.72) [n Z 20]
Germany
Pre-omalizumab,b mean (SD) 5.5 (8.82) [n Z 95] 6.4 (11.72) [n Z 47] 4.6 (4.42) [n Z 47]
Post-omalizumab,c mean (SD) 0.7 (1.58) [n Z 95] 0.5 (1.18) [n Z 49] 0.9 (1.91) [n Z 45]
Change, mean (SD) 5.0 (8.97) [n Z 91] 6.0 (11.68) [n Z 46] 3.8 (4.74) [n Z 44]
Combined
Pre-omalizumab,b mean (SD) 5.7 (8.28) [n Z 148] 5.9 (9.49) [n Z 77] 5.4 (6.81) [n Z 70]
Post-omalizumab,c mean (SD) 1.9 (3.88) [n Z 152] 1.6 (3.66) [n Z 81] 2.2 (4.14) [n Z 70]
Change, mean (SD) 3.9 (8.15) [n Z 141] 4.4 (10.20) [n Z 76] 3.3 (4.75) [n Z 64]
OCS, oral corticosteroids; SD, standard deviation.
a Defined as decline in FEV1 to <60% of personal best, requiring OCS burst and unscheduled doctor/emergency visit or hospitalization.
b Number of exacerbations per patient during the 12-months prior to omalizumab treatment.
c Number of exacerbations per patient during the observation period (annualized).
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Germany, and in those who reduced/stopped OCS compared
with those who maintained/increased OCS use. However, in
German patients a slightly larger decrease in exacerbations
was observed compared with those from France.Discussion
This pooled analysis has shown the OCS-sparing potential of
omalizumab in patients with severe allergic (IgE-mediated)
asthma being treated in France and Germany. Approxi-
mately half of the patients on maintenance OCS at baseline
were able to stop or reduce their OCS dose.
The reduction in OCS observed in this real-life analysis is
in agreement with the observations from various clinicalTable 4 Asthma-related hospitalizations in patients receiving m
Overall population
France
Pre-omalizumab,a mean (SD) 1.5 (2.32) [n Z 62]
Post-omalizumab,b mean (SD) 0.9 (3.27) [n Z 64]
Change, mean (SD) 0.6 (2.48) [n Z 62]
Germany
Pre-omalizumab,a mean (SD) 0.6 (1.11) [n Z 96]
Post-omalizumab,b mean (SD) 0.1 (0.72) [n Z 96]
Change, mean (SD) 0.5 (1.31) [n Z 91]
Combined
Pre-omalizumab,a mean (SD) 1.0 (1.75) [n Z 158]
Post-omalizumab,b mean (SD) 0.5 (2.17) [n Z 160]
Change, mean (SD) 0.5 (1.87) [n Z 153]
OCS, oral corticosteroids; SD, standard deviation.
a Number of asthma-related hospitalizations per patient during the
b Number of asthma-related hospitalizations per patient during thetrials of omalizumab. In one large study, patients (nZ 317)
with moderate-to-severe allergic asthma received high-
dose or low-dose omalizumab, or placebo; 33% and 43% of
patients in the high-dose and low-dose groups were able to
stop OCS use, compared with 17% of those on placebo.13 In
a pooled analysis of clinical trials, omalizumab has also
been shown to significantly reduce the need for rescue OCS
bursts compared with placebo.14 One study failed to show
a significant decrease in OCS use following omalizumab
therapy, as shown by a non-significant reduction in
exacerbations (defined as a worsening of asthma requiring
treatment with OCS) compared with placebo.15
The effectiveness of omalizumab at reducing exacerba-
tions and hospitalizations was also shown, irrespective of
change in OCS dose. These results suggest that the efficacy
of omalizumab demonstrated in clinical studies can beaintenance OCS at baseline.
Hospitalizations/patient/year
Patients who reduced/
stopped OCS
Patients who maintained/
increased OCS
1.1 (1.25) [n Z 33] 2.1 (3.05) [n Z 29]
0.5 (2.28) [n Z 34] 1.4 (4.12) [n Z 30]
0.5 (2.26) [n Z 33] 0.7 (2.74) [n Z 29]
0.7 (1.26) [n Z 47] 0.5 (0.94) [n Z 48]
0.1 (0.51) [n Z 49] 0.1 (0.90) [n Z 46]
0.7 (1.34) [n Z 46] 0.3 (1.29) [n Z 44]
0.9 (1.26) [n Z 80] 1.1 (2.15) [n Z 77]
0.3 (1.51) [n Z 83] 0.6 (2.73) [n Z 76]
0.6 (1.77) [n Z 79] 0.5 (1.98) [n Z 73]
12-months prior to omalizumab treatment.
observation period (annualized).
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parallel to those observed in clinical trials.
Although real-life studies are required to supplement
clinical trials, their main limitation is the lack of placebo
comparison. In this analysis while there was no comparison
with a control group, effectiveness during treatment was
compared to the previous year.
Prescribing practices were generally similar in France
and Germany and thus reflect real-life conditions of use.
It is reassuring that the results hold across different
countries, but it should be noted that in France a greater
proportion of patients were receiving maintenance OCS and
the daily OCS dose was nearly twice that prescribed to
German patients. Therefore, it is not possible to draw any
meaningful conclusions from a direct comparison of results
between countries. The overall beneficial effect is however
supportive of a likely general benefit in the population with
severe allergic (IgE-mediated) asthma.
Although reducing maintenance OCS is important to
improve asthma management, there are a few safety
issues to consider when rapidly reducing steroid therapy.
Patients with severe asthma may rarely present with
systemic hypereosinophilic syndrome or allergic eosinophilic
granulomatous vasculitis (Churg-Strauss syndrome), both of
which can usually be treated with systemic corticosteroids.
Therefore, as with other anti-asthma therapies, physicians
treating with omalizumab should be alert to the develop-
ment of marked eosinophilia or vasculitis, particularly
following a rapid reduction in maintenance OCS.8
To conclude, European real-life experience demon-
strates the OCS-sparing potential of omalizumab in some
patients with severe allergic (IgE-mediated) asthma.
Despite this reduced OCS use, asthma control is improved
as shown by a reduction in asthma-related events. Omali-
zumab may therefore decrease the potential for steroid-
associated morbidities in patients with inadequately
controlled severe allergic asthma.
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